Pancreatic cancer incidence was evaluated using SEER multiple-primary standardized incidence ratio (MP-SIR) methodology with a 12-month latency exclusion to minimize synchronous detection and surveillance bias. Expected counts were derived from age, calendar year, and registry-specific population rates. *: Excess risk per 10,000 person-years; † :exact CIs available from SEER output; shown approximately here for layout consistency.
Declarations
Author contributions
SL: Conceptualization, Methodology, Formal analysis, Data curation, Investigation, Visualization, Writing—original draft, Writing—review & editing. PHR: Conceptualization, Methodology, Data curation, Writing—review & editing. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.
Conflicts of interest
The authors declare that they have no competing interests.
Ethical approval
This study analyzed de-identified, publicly available secondary data and did not involve interaction with human participants or access to identifiable private information. The use of SEER Research Data is governed by the National Cancer Institute Data-Use Agreement, and FAERS data accessed via OpenVigil are publicly available and fully anonymized. In accordance with U.S. federal regulations (45 CFR 46) and institutional policies, this study was determined to be exempt from Institutional Review Board (IRB) review, and informed consent was not required. The study was conducted in accordance with the Declaration of Helsinki.
Consent to participate
Not required.
Consent to publication
Not required.
Availability of data and materials
The data analyzed in this study are derived from publicly accessible resources. Cancer incidence data were obtained from the Surveillance, Epidemiology, and End Results (SEER) Research Data program (SEER Research Plus Data, 8 Registries, November 2024 submission; diagnoses 1975–2022), available to qualified investigators through the National Cancer Institute upon execution of a SEER Research Data Agreement. Pharmacovigilance analyses were conducted using OpenVigil 2.1, which provides curated access to the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. UK Biobank analyses were conducted under approved application access (application number 57245). UK Biobank data are available to bona fide researchers for health-related research in the public interest upon project approval through the UK Biobank Research Analysis Platform (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). Derived variables and analytical code from this study are available from the corresponding author upon reasonable request, subject to compliance with UK Biobank data sharing policies. All analyses were performed on de-identified, aggregated data. No individual-level participant data are publicly shared by the authors.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Cao Y, Zhao R, Guo K, Ren S, Zhang Y, Lu Z, et al. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma.Front Oncol. 2022;11:744667. [DOI] [PubMed] [PMC]
Guo K, Ren S, Zhang H, Cao Y, Zhao Y, Wang Y, et al. Biomimetic Gold Nanorods Modified with Erythrocyte Membranes for Imaging-Guided Photothermal/Gene Synergistic Therapy.ACS Appl Mater amp; Interfaces. 2023;15:25285–99. [DOI] [PubMed]
Ren S, Qin B, Daniels MJ, Zeng L, Tian Y, Wang ZQ. Developing and validating a computed tomography radiomics strategy to predict lymph node metastasis in pancreatic cancer.World J Radiol. 2025;17:109373. [DOI] [PubMed] [PMC]
Kane S, Engelhart A, Guadagno J, Jones A, Usoro I, Brutcher E. Pancreatic Ductal Adenocarcinoma: Characteristics of Tumor Microenvironment and Barriers to Treatment.J Adv Pract Oncol. 2020;11:693–8. [DOI] [PubMed] [PMC]
Rauschenberg S, Orgler-Gasche E, Karakas Zeybek D, Regel I, Löhr JM, Öhlund D, et al. Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review).Int J Oncol. 2026;68:e68. [DOI] [PubMed] [PMC]
Archibugi L, Graglia B, Valente R, Stigliano S, Roberto M, Capalbo C, et al. Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study.Pancreatology. 2020;20:1149–54. [DOI] [PubMed]
Liu L, Wang X, Guo D, Ma R, Gong H, Wang C. Hormone replacement therapy and risk of pancreatic cancer in postmenopausal women: Evidence from the US National Inpatient Sample 2008–2018.Heliyon. 2024;10:e37588. [DOI] [PubMed] [PMC]
Manoukian P, van Schie DM, van Schelt AS, Wassenaar NPM, Dings MPG, Lansbergen MF, et al. Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment.Cancer Res. 2025;86:571–86. [DOI] [PubMed] [PMC]
Veghini L, Corbo V. Estrogen Shapes Fibroblast States to Limit Pancreatic Cancer Aggressiveness.Cancer Res. 2026;86:567–8. [DOI] [PubMed]
Böhm R, Bulin C, Waetzig V, Cascorbi I, Klein HJ, Herdegen T. Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections.Br J Clin Pharmacol. 2021;87:4421–31. [DOI] [PubMed]
Böhm R, Höcker J, Cascorbi I, Herdegen T. OpenVigil—free eyeballs on AERS pharmacovigilance data.Nat Biotechnol. 2012;30:137–8. [DOI] [PubMed]
Böhm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, et al. OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.PLOS ONE. 2016;11:e0157753. [DOI] [PubMed] [PMC]
Giunchi V, Fusaroli M, Hauben M, Raschi E, Poluzzi E. Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach.Drug Saf. 2023;46:921–6. [DOI] [PubMed]
Wang W. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study.Biosci Rep. 2019;39:e39. [DOI] [PubMed] [PMC]
Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.Pharmacoepidemiol Drug Saf. 2001;10:483–6. [DOI] [PubMed]
Ghabache B, Cole J, Vasireddy S. Pancreatic cancer in breast cancer patients: Incidence and relation with hormone receptor status.J Clin Oncol. 2007;25:17079. [DOI]
